What is PBYI's P/E ratio?

PUMA BIOTECHNOLOGY INC (PBYI) currently trades at a P/E ratio of 14.27.

PUMA BIOTECHNOLOGY INC reports a Return on Equity (ROE) of 18.99%.

What is PBYI's dividend yield?

PUMA BIOTECHNOLOGY INC offers a dividend yield of 0.00%.

What is PBYI's Quality Score?

Our AI rates PBYI's overall financial quality at 69 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy PBYI?

Our AI Timing Score for PBYI is 69 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does PBYI belong to?

PUMA BIOTECHNOLOGY INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

PBYI (NASDAQ) Stock Analysis | PUMA BIOTECHNOLOGY INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

PBYI AI Analysis Summary

Our AI summary for PBYI: PUMA BIOTECHNOLOGY INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 14.27, ROE of 18.99%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 69/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

PBYI

PUMA BIOTECHNOLOGY INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 89

USD 7.93

0.04 (0.51%) Day Change

Watchlist Portfolio Compare Chart

14.27

P/E

0.09

D/E

19.0%

ROE

12.7%

ROA

0.00%

Div Yield

PUMA BIOTECHNOLOGY INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 7.93 Price 0.04 (0.51%) Day Change	NEWS SCORE: 89

PBYI, the overall quality is ok ( Quality = 69) and the timing to buy is ...(Sign In to See)...

Loading chart...

69 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: Negative growth of ROE in the last year.
ROE is decreasing significantly
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

54%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	89
Magic Formula Rank by ROA	434
Magic Formula Rank by ROE	434
Magic Formula Rank by ROIC	343
Price	7.93
PBV / Sector	3.13 / 5.20
Earning Per Share	0.48

PE / Sector	14.27 / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	2.73 M GREAT
Average 1W Daily Value	1.78 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	10.73 / 98.71
NPM Average (%) / Sector	9.33 / -1,721.76
NPM Change Average (%) / Sector	261,157.41 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	12.65 / 27.02
ROA Average (%) / Sector	10.12 / -368.17
ROA Change Average (%) / Sector	259,957.75 / 5,404.12 GREAT
ROE (%) / Sector	18.99 / 3.47
ROE Average (%) / Sector	23.23 / 6.51 GOOD
ROE Change Average (%) / Sector	109,080.97 / 2,128.13 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:18
Symbol	PBYI
Name	PUMA BIOTECHNOLOGY INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	50.90 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	401.60 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024

Phone: 424 248 6500

Website: https://www.pumabiotechnology.com

Employees: 179

Sector: Healthcare >> Biotechnology

Description: Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.